These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15131530)

  • 1. Coronary heart disease and lipid-modifying treatment in African American patients.
    Ferdinand KC
    Am Heart J; 2004 May; 147(5):774-82. PubMed ID: 15131530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Issues in minority health: atherosclerosis and coronary heart disease in African Americans.
    Clark LT
    Med Clin North Am; 2005 Sep; 89(5):977-1001, 994. PubMed ID: 16129108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program.
    Grundy SM; Cleeman JI; Rifkind BM; Kuller LH
    Arch Intern Med; 1999 Aug 9-23; 159(15):1670-8. PubMed ID: 10448768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III.
    Talbert RL
    Am J Manag Care; 2002 Sep; 8(12 Suppl):S301-7. PubMed ID: 12240701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective management of patients with dyslipidemia.
    Lipsy RJ
    Am J Manag Care; 2003 Feb; 9(2 Suppl):S39-58. PubMed ID: 12597240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major CHD risk factors predominate among African-American women who are eligible for lipid-lowering drug therapy under the new ATP III guidelines.
    Koro CE; L'italien GJ; Fedder DO
    Eur J Cardiovasc Prev Rehabil; 2004 Oct; 11(5):376-81. PubMed ID: 15616409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of high serum cholesterol and related disorders in patients at risk for coronary heart disease.
    Grundy SM
    Am J Med; 1997 Feb; 102(2A):15-22. PubMed ID: 9217581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment challenges in hypercholesterolemia.
    Pauciullo P; Mancini M
    Cardiovasc Drugs Ther; 1998 Sep; 12(4):325-37. PubMed ID: 9825176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is lipid-lowering therapy underused by African Americans at high risk of coronary heart disease within the VA health care system?
    Woodard LD; Kressin NR; Petersen LA
    Am J Public Health; 2004 Dec; 94(12):2112-7. PubMed ID: 15569962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors, barriers, and facilitators of lipid-lowering medication use among African Americans in a primary care clinic.
    Schwartz KL; Dailey R; Bartoces M; Binienda J; Archer C; Neale AV
    J Natl Med Assoc; 2009 Sep; 101(9):944-52. PubMed ID: 19806853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
    Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
    Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Lipsy RJ
    J Manag Care Pharm; 2003; 9(1 Suppl):2-5. PubMed ID: 14613351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Traditional coronary risk factors in African Americans.
    Potts JL; Thomas J
    Am J Med Sci; 1999 Mar; 317(3):189-92. PubMed ID: 10100693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Untreated hypercholesterolemia in an emergency department chest pain observation unit population.
    Chandra A; Compton S; Sochor M; Puri S; Zalenski RJ
    Acad Emerg Med; 2002 Jul; 9(7):699-702. PubMed ID: 12093710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypercholesterolemia. Is lipid-lowering worthwhile for older patients?
    Deedwania PC
    Geriatrics; 2000 May; 55(5):22-8. PubMed ID: 10826262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic alternatives for the management of dyslipidemia.
    Cassagnol M; Ezzo D; Patel PN
    J Pharm Pract; 2013 Dec; 26(6):528-40. PubMed ID: 24142496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.